Argenx
Clinical trials sponsored by Argenx, explained in plain language.
Biopharmaceutical company developing antibody therapies for autoimmune diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a new injection calm Sjogren's nerve damage?
Disease control Not yet recruitingThis trial tests whether an experimental drug called efgartigimod can reduce nerve damage and pain in adults with Sjogren's disease. Participants will receive either the drug or a placebo as a subcutaneous injection. The study measures changes in neuropathy symptoms and quality o…
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a new Antibody-Lowering drug ease autoimmune brain inflammation?
Disease control Not yet recruitingThis Phase 2 trial tests efgartigimod PH20 SC, a drug that lowers harmful antibodies, in 170 adults and teens with autoimmune encephalitis (AIE). Participants receive either the drug or a placebo, and researchers measure changes in disability and symptoms over up to 3 years. The …
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new infusion ease muscle weakness in rare genetic disorders?
Disease control Not yet recruitingThis Phase 3 trial is testing whether an experimental drug called adimanebart can help people aged 12 and older with certain congenital myasthenic syndromes (CMS) feel better and do daily activities more easily. Participants are randomly assigned to receive either adimanebart or …
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for teens with rare nerve disease: drug trial launches
Disease control Not yet recruitingThis study tests a new medicine called empasiprubart in teenagers aged 12 to 17 who have a rare nerve disease called CIDP. The goal is to find the right dose and see if the drug is safe and helps control the disease. Participants will receive the drug for about 27 months and be f…
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC